Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Nov-Dec;13(6):438-43.
doi: 10.1002/(sici)1098-2388(199711/12)13:6<438::aid-ssu8>3.0.co;2-b.

Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up

H Ragde  1 , J C Blasko, P D Grimm, G M Kenny, J Sylvester, D C Hoak, W Cavanagh, K Landin
Affiliations

Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up

H Ragde et al. Semin Surg Oncol. 1997 Nov-Dec.

Erratum in

  • Semin Surg Oncol 1998 Mar;14(2):185

Abstract

In recent years, there has been a resurgence of interest in interstitial radiation as a cost-effective and efficient method of treating organ-confined prostate cancer. We describe our 7- and 8-year results with transperineal Iodine-125 and Palladium-103 implantation. A total of 551 consecutive patients were treated. Of these, 320/551 (58%) received implant alone (Group I), and 231/551 (42%)--considered higher risk patients--were also treated with a modest dose (45 Gy) of external beam irradiation (Group II). The median follow-up for Group I was 55 months, and for Group II, 60 months. At 7 years, the actuarial freedom from biochemical failure (prostate-specific antigen (PSA) < or = 1.0 ng/mL) was 80% in Group I patients, and, at 8 years, 65% in Group II patients. Morbidity was minimal if patients had not undergone prior transurethral prostate resections. The results indicate that interstitial radiation is a valid treatment for clinically localized prostate cancer.

PubMed Disclaimer

LinkOut - more resources